SHILPA MEDICARE LTD. - 530549 - Intimation For Participation In Investor Conference
Intimation for Participation in Investor Conference12-06-2024
12-06-2024
SHILPA MEDICARE LTD. - 530549 - Type IV DMF (Drug Master File) Of Recombinant Human Albumin 20%
Shilpa Biologicals files Type IV DMF (Drug Master File) of recombinant Human Albumin 20%04-06-2024
SHILPA MEDICARE LTD. - 530549 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Annual Secretarial Compliance Report of the Company for the financial year 2023-24 issued by Mr.D S Rao, Practicing Company Secretary.29-05-2024
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Q4 FY 24 conference call28-05-2024
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of Q4 FY 24 conference call24-05-2024
Shilpa Medicare Results Earnings Call for Q4FY24
Conference Call with Shilpa Medicare Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.24-05-2024
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor presentation for the quarter and year ended 31 March 202424-05-2024
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation of the Company for the quarter and year ended 31 March 202423-05-2024
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation of the Company for the quarter and year 31 March 202423-05-2024
SHILPA MEDICARE LTD. - 530549 - Audited Financial Results For The Quarter And Year Ended 31 March 2024
Audited Standalone & Consolidated Financial results for the quarter and year ended 31 March 202423-05-2024